Appleton Partners Incma buys $9,925,885 stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Appleton Partners Incma scooped up 533 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 67,592 shares of Thermo Fisher Scientific which is valued at $9,925,885.Thermo Fisher Scientific makes up approximately 1.93% of Appleton Partners Incma’s portfolio.

Thermo Fisher Scientific opened for trading at $145.61 and hit $147.7521 on the upside on Wednesday, eventually ending the session at $147.14, with a gain of 1.05% or 1.53 points. The heightened volatility saw the trading volume jump to 14,97,750 shares. Company has a market cap of $58,306 M.

Other Hedge Funds, Including , Winslow Evans Crocker reduced its stake in TMO by selling 136 shares or 4.64% in the most recent quarter. The Hedge Fund company now holds 2,796 shares of TMO which is valued at $410,593. Thermo Fisher Scientific makes up approx 0.12% of Winslow Evans Crocker’s portfolio.Gateway Investment Advisers reduced its stake in TMO by selling 13,122 shares or 29.38% in the most recent quarter. The Hedge Fund company now holds 31,548 shares of TMO which is valued at $4,632,824. Thermo Fisher Scientific makes up approx 0.04% of Gateway Investment Advisers’s portfolio.Cedar Hill Associates boosted its stake in TMO in the latest quarter, The investment management firm added 1,640 additional shares and now holds a total of 141,327 shares of Thermo Fisher Scientific which is valued at $20,540,466. Thermo Fisher Scientific makes up approx 3.54% of Cedar Hill Associates’s portfolio.Chelsea Counsel Co reduced its stake in TMO by selling 4,110 shares or 7.73% in the most recent quarter. The Hedge Fund company now holds 49,073 shares of TMO which is valued at $6,951,681. Thermo Fisher Scientific makes up approx 2.01% of Chelsea Counsel Co’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.